Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As axons myelinate, establish a stable neurofilament network, and expand in caliber, neurofilament proteins are extensively phosphorylated along their C-terminal tails, which is recognized by the monoclonal antibody, RT-97. Here, we demonstrate in vivo that RT-97 immunoreactivity (IR) is generated by phosphorylation at KSPXK or KSPXXXK motifs and requires flanking lysines at specific positions. extracellular signal regulated kinase 1,2 (ERK1,2) and pERK1,2 levels increase in parallel with phosphorylation at the RT-97 epitope during early postnatal brain development. Purified ERK1,2 generated RT-97 on both KSP motifs on recombinant NF-H tail domain proteins, while
cdk5
phosphorylated only KSPXK motifs. RT-97 epitope generation in primary hippocampal neurons was regulated by extensive cross-talk among ERK1,2, c-Jun N-terminal kinase 1,2 (JNK1,2) and
cdk5
. Inhibition of both ERK1,2 and JNK1,2 completely blocked RT-97 generation. Cdk5 influenced RT-97 generation indirectly by modulating JNK activation. In mice,
cdk5
gene deletion did not significantly alter RT-97 IR or ERK1,2 and JNK activation. In mice lacking the
cdk5
activator
P35
, the partial suppression of
cdk5
activity increased RT-97 IR by activating ERK1,2. Thus,
cdk5
influences RT-97 epitope generation partly by modulating ERKs and JNKs, which are the two principal kinases regulating neurofilament phosphorylation. The regulation of a single target by multiple protein kinases underscores the importance of monitoring other relevant kinases when the activity of a particular one is blocked.
...
PMID:Neurofilament tail phosphorylation: identity of the RT-97 phosphoepitope and regulation in neurons by cross-talk among proline-directed kinases. 1871 69
A high-affinity inhibitor protein called CIP, produced by small truncations of p35, was experimentally identified.
P35
is a physiological activator of the cyclin-dependent kinase
cdk5
. P25 is derived from proteolytic truncation of p35 within "stressed" neurons, and it is associated with the hyperphosphorylation of specific neuronal proteins, typically occurring in neurodegenerative diseases such as Alzheimer's. Here, we report a study of the binding mechanisms of the
cdk5
-p25 and
cdk5
-CIP complexes. This provides a better understanding of the source of the inhibitory activity of the protein CIP. We use a geometry-based technique to test the hypothesis that p25's truncation increases the flexibility of CIP and thus prevents
cdk5
from reaching its active conformation. Our study is based on a geometry-based alignment algorithm, which aligns two given protein conformations with respect to their interfaces. Our results support the flexibility hypothesis and will be used as a basis for targeted molecular dynamics simulations.
...
PMID:Evaluation of the interaction of cyclin-dependent kinase 5 with activator p25 and with p25-derived inhibitor CIP. 2050 23
Cyclin-dependent kinase 5 (Cdk5) was identified almost two decades ago as a Tau kinase specific to the nervous system. Shortly after its discovery, it was revealed that this atypical member of the
CDK
family does not partner with cyclins but with two other proteins, p35 and p39.
P35
is predominantly expressed in post-mitotic neurons, whereas p39 is expressed in many different tissues including the brain, pancreas, muscle cells, neutrophils, and many other cell types. A proline-directed serine/threonine (S/T) kinase, predominantly active in the nervous system, Cdk5 regulates a multitude of functions including nervous system development, neuronal migration, cytoskeletal dynamics, axonal guidance, synaptic plasticity, neurotransmission, neuronal survival and death, to mention a few. In association with its ubiquitous expression in other tissues, Cdk5 is implicated in a wide range of functions, such as gene transcription, vesicular transport, apoptosis, cell adhesion, migration, exocytosis, etc. A focal point of investigation surrounding Cdk5 is its deregulation in pathogenic processes of neurodegenerative disorders, which has emphasized on its hyperactivation by p25, a calpain-cleaved product of p35 leading to Tau and neurofilament hyperphosphorylation followed by neuronal death. What has intrigued researchers about Cdk5 is its tight regulation in carrying out many normal physiological functions while its deregulation under pathological conditions, is linked to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Neiman Pick's Type C disease and others. Between these two so-called 'good Cdk5 (Cdk5/p35)' and 'bad Cdk5 (Cdk5/p25)', the latter has become the target for therapeutic intervention in neurodegenerative disorders.
...
PMID:Special Issue on "Cdk5 and Brain Disorders": Prologue. 2806 92